295 related articles for article (PubMed ID: 25893308)
1. IGFBP2 potentiates nuclear EGFR-STAT3 signaling.
Chua CY; Liu Y; Granberg KJ; Hu L; Haapasalo H; Annala MJ; Cogdell DE; Verploegen M; Moore LM; Fuller GN; Nykter M; Cavenee WK; Zhang W
Oncogene; 2016 Feb; 35(6):738-47. PubMed ID: 25893308
[TBL] [Abstract][Full Text] [Related]
2. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.
Li T; Zhang C; Zhao G; Zhang X; Hao M; Hassan S; Zhang M; Zheng H; Yang D; Liu L; Mehraein-Ghomi F; Bai X; Chen K; Zhang W; Yang J
Cancer Lett; 2020 May; 477():19-30. PubMed ID: 32120023
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.
Lo HW; Cao X; Zhu H; Ali-Osman F
Mol Cancer Res; 2010 Feb; 8(2):232-45. PubMed ID: 20145033
[TBL] [Abstract][Full Text] [Related]
4. JNK mediates insulin-like growth factor binding protein 2/integrin alpha5-dependent glioma cell migration.
Mendes KN; Wang GK; Fuller GN; Zhang W
Int J Oncol; 2010 Jul; 37(1):143-53. PubMed ID: 20514406
[TBL] [Abstract][Full Text] [Related]
5. IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma.
Liu Y; Li F; Yang YT; Xu XD; Chen JS; Chen TL; Chen HJ; Zhu YB; Lin JY; Li Y; Xie XM; Sun XL; Ke YQ
Oncogene; 2019 Mar; 38(11):1815-1831. PubMed ID: 30368528
[TBL] [Abstract][Full Text] [Related]
6. STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3.
Han W; Carpenter RL; Cao X; Lo HW
Mol Carcinog; 2013 Dec; 52(12):959-69. PubMed ID: 22693070
[TBL] [Abstract][Full Text] [Related]
7. Dobesilate inhibits the activation of signal transducer and activator of transcription 3, and the expression of cyclin D1 and bcl-XL in glioma cells.
Cuevas P; Díaz-González D; Sánchez I; Lozano RM; Giménez-Gallego G; Dujovny M
Neurol Res; 2006 Mar; 28(2):127-30. PubMed ID: 16551428
[TBL] [Abstract][Full Text] [Related]
8. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage.
Zhou Z; Lu H; Zhu S; Gomaa A; Chen Z; Yan J; Washington K; El-Rifai W; Dang C; Peng D
J Exp Clin Cancer Res; 2019 Jan; 38(1):13. PubMed ID: 30626422
[TBL] [Abstract][Full Text] [Related]
9. Regulation of β-catenin by IGFBP2 and its cytoplasmic actions in glioma.
Verma BK; Kondaiah P
J Neurooncol; 2020 Sep; 149(2):209-217. PubMed ID: 32803659
[TBL] [Abstract][Full Text] [Related]
10. TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma.
Lv D; Li Y; Zhang W; Alvarez AA; Song L; Tang J; Gao WQ; Hu B; Cheng SY; Feng H
Nat Commun; 2017 Nov; 8(1):1454. PubMed ID: 29129908
[TBL] [Abstract][Full Text] [Related]
11. TRIM59 Promotes Gliomagenesis by Inhibiting TC45 Dephosphorylation of STAT3.
Sang Y; Li Y; Song L; Alvarez AA; Zhang W; Lv D; Tang J; Liu F; Chang Z; Hatakeyama S; Hu B; Cheng SY; Feng H
Cancer Res; 2018 Apr; 78(7):1792-1804. PubMed ID: 29386185
[TBL] [Abstract][Full Text] [Related]
12. Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies.
Phillips LM; Zhou X; Cogdell DE; Chua CY; Huisinga A; R Hess K; Fuller GN; Zhang W
J Pathol; 2016 Jul; 239(3):355-64. PubMed ID: 27125842
[TBL] [Abstract][Full Text] [Related]
13. RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma.
Yeom SY; Nam DH; Park C
Mol Cancer Ther; 2014 Dec; 13(12):3049-61. PubMed ID: 25313011
[TBL] [Abstract][Full Text] [Related]
14. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor binding protein 2 promotes glioma development and progression.
Dunlap SM; Celestino J; Wang H; Jiang R; Holland EC; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11736-41. PubMed ID: 17606927
[TBL] [Abstract][Full Text] [Related]
16. EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.
Oldrini B; Hsieh WY; Erdjument-Bromage H; Codega P; Carro MS; Curiel-García A; Campos C; Pourmaleki M; Grommes C; Vivanco I; Rohle D; Bielski CM; Taylor BS; Hollmann TJ; Rosenblum M; Tempst P; Blenis J; Squatrito M; Mellinghoff IK
Nat Commun; 2017 Dec; 8(1):2035. PubMed ID: 29229958
[TBL] [Abstract][Full Text] [Related]
17. Expression of insulin-like growth factor binding protein genes and its hypoxic regulation in U87 glioma cells depends on ERN1 mediated signaling pathway of endoplasmic reticulum stress.
Minchenko DO; Kharkova AP; Karbovskyi LL; Minchenko OH
Endocr Regul; 2015 Apr; 49(2):73-83. PubMed ID: 25960008
[TBL] [Abstract][Full Text] [Related]
18. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.
Fan QW; Cheng CK; Gustafson WC; Charron E; Zipper P; Wong RA; Chen J; Lau J; Knobbe-Thomsen C; Weller M; Jura N; Reifenberger G; Shokat KM; Weiss WA
Cancer Cell; 2013 Oct; 24(4):438-49. PubMed ID: 24135280
[TBL] [Abstract][Full Text] [Related]
19. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation.
Lindemann C; Hackmann O; Delic S; Schmidt N; Reifenberger G; Riemenschneider MJ
Acta Neuropathol; 2011 Aug; 122(2):241-51. PubMed ID: 21590492
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network.
Holmes KM; Annala M; Chua CY; Dunlap SM; Liu Y; Hugen N; Moore LM; Cogdell D; Hu L; Nykter M; Hess K; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2012 Feb; 109(9):3475-80. PubMed ID: 22345562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
